HOLON, Israel, March 26, 2019 /PRNewswire/ -- Compugen
Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy
company and leader in predictive target discovery, today announced
that its entire board of directors and members of management
purchased Company shares on the open market during March
2019.
"My fellow board members and I are excited about Compugen's
unique value proposition, its proven computational discovery
platform, and differentiated therapeutic pipeline that is designed
to address significant unmet needs in immuno-oncology," said
Paul Sekhri, Chairman of the Board.
"We have the highest confidence in this management team and
employees whose talent and dedication made possible the
acomplishments of 2018, including the intiation of two clinical
trials as well as partnerships with Bristol-Myers Squibb and
AstraZeneca. We believe the Company is well positioned, now more
than ever, for future significant growth and success."
About Compugen
Compugen is a clinical-stage, therapeutic discovery and
development company utilizing its broadly applicable computational
discovery platforms to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered
computationally, including T cell immune checkpoints and other
early-stage immuno-oncology programs focused largely on myeloid
targets. Compugen's business model is to enter into collaborations
for its novel targets and related drug product candidates at
various stages of research and development. The Company is
headquartered in Israel with
facilities in South San Francisco,
CA. Compugen's ordinary shares are listed on Nasdaq and the
Tel Aviv Stock Exchange under the ticker symbol CGEN. For
additional information, please visit Compugen's corporate website
at www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," "confident," and "intends," and describe opinions about
possible future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent
on entering into collaboration agreements with third parties and
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
advance or receive regulatory approval. These and other factors,
including the ability to finance the Company, are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission (SEC) as well as other documents that may be
subsequently filed by Compugen from time to time with the SEC. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate
Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Burns McClellan,
Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-announces-purchase-of-company-shares-by-its-board-of-directors-and-members-of-management-300818425.html
SOURCE Compugen Ltd.